Centessa Pharmaceuticals plc — Director's Dealing 2025

Feb 4, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2025-02-01

Reporting Person: Anderson Karen M. (Chief People Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-01	Ordinary Shares	F	10732	$16.92	Disposed	60793	Direct
2025-02-03	Ordinary Shares	S	6471	$16.8636	Disposed	54322	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-03	Share Option (right to buy)	$16.90	A	120000	Acquired	2035-02-03	Ordinary Shares (120000)	Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.

F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2024.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.22 to $17.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 3, 2025.